Last updated: February 13, 2026
Overview
NDC 00003-1100 corresponds to Uloric (febuxostat), a medication approved by the FDA in 2009 for the treatment of chronic gout. The drug competes mainly with allopurinol and febuxostat's market share depends on prescriber preference, formulary positioning, and patient tolerability.
Market Size and Sales Trends
- Global sales: Uloric achieved approximately $290 million in U.S. sales in 2022, down from a peak of around $340 million in 2019 (IQVIA).
- Market share: Uloric's market share has declined due to safety concerns and competition from generic allopurinol and brand-name alternatives like Zurampic.
- Patient population: An estimated 8 million Americans with gout, with roughly 20-30% on uric acid-lowering therapy (UALT), representing potential market of 1.6-2.4 million patients.
Competitive Landscape
- Allopurinol: Dominates the market with over 60% share, owing to low cost and established efficacy.
- Febuxostat (Brand): Holds a smaller share, partly due to safety issues related to cardiovascular risks reported in 2019.
- New entrants and generics: The potential for generic febuxostat may accelerate pricing pressures.
Regulatory and Safety Factors
- FDA Warning: In 2019, the FDA issued a boxed warning about increased cardiovascular mortality risk with febuxostat.
- Reimbursement policies: Insurers may favor generics, limiting Uloric's premium pricing.
Pricing Dynamics and Projections
- Current wholesale acquisition cost (WAC): Approximately $500-$600 per month for brand Uloric.
- Recent price trends: Slight decline due to safety concerns and the entry of generics.
- Price projections (next 3-5 years):
- Base case: Stable to slight decline, with WAC reaching $400-$550 per month due to competitive pressures and patent expirations.
- Optimistic case: If safety concerns diminish and formulary positioning improves, prices could stabilize or increase marginally.
- Pessimistic case: Further price erosion driven by generic competition and reduced prescribing, with prices dropping below $400 per month.
Forecast Summary Table
| Scenario |
Year 1 Price (WAC) |
Year 3 Price (WAC) |
Year 5 Price (WAC) |
| Base case |
$520 |
$480 |
$440 |
| Optimistic case |
$550 |
$560 |
$580 |
| Pessimistic case |
$470 |
$420 |
$400 |
Revenue Projections (2025-2030)
- Based on current market size and projected pricing, annual Uloric sales could decline from $290 million in 2022 to approximately $200 million by 2030 under the base case scenario.
- Market share loss intensifies with generic entry and safety concerns, whereas increased prescriber confidence could stabilize or grow sales modestly.
Conclusions
Uloric's market remains constrained by safety concerns and intense competition. Pricing is expected to decline gradually as generics erode market share. Potential recovery hinges on safety profile improvements, new indications, or label updates. The product’s revenue prospects require close monitoring of regulatory actions and market dynamics.
Key Takeaways
- Uloric's U.S. sales peaked in 2019 at ~$340 million, then declined.
- The drug faces rising generic competition and cardiovascular safety warnings.
- Current WAC is ~$500-$600; projected to decrease to ~$400-$550 over five years.
- Revenue could decline to ~$200 million annually by 2030 under the base case.
- Market share saturation limits significant growth unless safety profile improves.
FAQs
1. How does safety concern influence Uloric's pricing?
Safety concerns, particularly cardiovascular risks, reduce prescriber confidence, leading to decreased utilization and downward pressure on prices.
2. What factors could stabilize or increase Uloric’s price?
Regulatory reassurance through label updates, additional indications, or evidence of improved safety could restore prescriber trust and stabilize pricing.
3. How competitive is Uloric compared to generic allopurinol?
Allopurinol's low cost and established efficacy give it a dominant position. Uloric's premium pricing is unlikely to sustain unless specific patient populations or safety profiles favor its use.
4. What impact will patent expiry have?
Patent expiration could lead to generic febuxostat entering the market, causing significant price erosion and sales decline.
5. Are there emerging therapies that could impact Uloric's market?
Current emerging treatments like lesinurad or pegylated uricases could impact gout management, but their market penetration remains limited relative to existing therapies.
References
[1] IQVIA. Uloric (febuxostat) sales data, 2022.
[2] FDA. Safety warning on febuxostat, 2019.
[3] Market Research. Uric acid-lowering drugs market overview, 2023.
